Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Cushing Syndrome 6Hypertension 5Diabetes Mellitus, Type 2 5ACTH Syndrome, Ectopic 5Pituitary ACTH Hypersecretion 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Adrenocortical Carcinoma 3Adrenal Cortex Neoplasms 3Prostatic Neoplasms 2Peritoneal Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Processes 1Ovarian Diseases 1Neoplasms by Site 1Hyperglycemia 1Glucose Intolerance 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Endocrine System Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Ovarian Epithelial 1Adrenocortical Hyperfunction 1Adrenal Gland Diseases 1Adenocarcinoma 1

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × relacorilant × Clear all
NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

University of Chicago

Phase 1 Completed
42 enrolled
Genitourinary

Prostatic Neoplasms

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

University of Chicago

Phase 2 Recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡